PharmaShots | Incisive News in 3 Shots

Subscribe Now

CymaBay

CymaBay Reports the EMA’s Acceptance to Review the MAA of Seladelpar for Treating Primary Biliary Cholangitis (PBC)

CymaBay Reports the EMA’s Acceptance to Review the MAA of Seladelpar for Treating Primary Biliary Cholangitis (PBC)

March 5, 2024

CymaBay Publishes Results for Seladelpar in P-III Trial for the Treatment of Primary Biliary Cholangitis in the NEJM

CymaBay Publishes Results for Seladelpar in P-III Trial for the Treatment of Primary Biliary Cholangitis in the NEJM

February 22, 2024

CymaBay Entered into a Collaboration and License Agreement with Kaken to Develop and Commercialize Seladelpar for Primary Biliary Cholangitis in Japan

CymaBay Entered into a Collaboration and License Agreement with Kaken to Develop and Commercialize Seladelpar for Primary Biliary...

January 9, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us